The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Phase of Trial: Phase III
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation
- Focus Registrational; Therapeutic Use
- Sponsors EyePoint Pharmaceuticals; Icon Bioscience
- 08 May 2019 Results presented in the EyePoint Pharmaceuticals media release.
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. acquired Icon Bioscience and subsequently changed its name to EyePoint Pharmaceuticals.
- 28 Mar 2018 Results presented in the EyePoint Pharmaceuticals media release.